Kalo te përmbajtja
  • EN
  • SQ
  • IT
  • FR
  • ES
  • DE
  • EL
VA-NEWS VA-NEWS
  • Home
  • News
  • Opinion
  • Health
  • Technology
  • Sport
  • Lifestyle
  • Entertainment
  • Travel
LIVE
Navigation

VA-NEWS

  • Home
  • News
  • Opinion
  • Health
  • Technology
  • Sport
  • Lifestyle
  • Entertainment
  • Travel
Shortcuts
Home Latest
LIVE
Gjuha
  • EN
  • SQ
  • IT
  • FR
  • ES
  • DE
  • EL

Search news

  1. Kryefaqja
  2. Health
  3. Depression: Escitalopram may be best option for long-term use
Health

Depression: Escitalopram may be best option for long-term use

• November 14, 2026 • 5 min read • 👁 2
◉ WhatsApp 𝕏 X
News

Antidepressants are some of the most commonly prescribed drugs in the United States, with active prescriptions lasting anywhere from a few weeks to several months or even years.

Identifying medications that can both alleviate symptoms and help maintain wellness is therefore an important part of long-term treatment for depression.

A new systematic review published in November in The Lancet Psychiatry compared the long-term effectiveness of 20 different drugs, comparing them against fluoxetine, a common antidepressant.

The researchers identified three medications associated with the highest rates of sustained response: escitalopram, agomelatine, and duloxetine.

These results could help clinicians and patients make more informed decisions when considering antidepressants, though the best antidepressant will still differ for each person based on individual circumstances.

Read more:Insomnia linked to 26% higher risk of stroke in new review

The researchers explored whether certain antidepressants were more effective at achieving sustained response than others.

They found that escitalopram, agomelatine, and duloxetine showed higher sustained response rates than fluoxetine.

To determine this, they analyzed evidence from 115 randomized controlled trials, with data from more than 30,000 participants.

They found that those taking escitalopram had 62% higher odds of lasting symptom relief compared with those taking fluoxetine.

Read more:Dementia: Simple blood test could indicate increased risk, study finds

People taking duloxetine and agomelatine had 57% and 40% higher odds of lasting improvement in symptoms, respectively.

Perry Anthony Maliuanag, MD, FAPA, psychiatrist in practice at Menlo Park Psychiatry & Sleep Medicine, spoke with Medical News Today about these medications.

“Escitalopram has one of the lowest drug-drug interactions and is considered best option for those with multiple medical co-morbidity on polypharmacy. Duloxetine is a dual acting antidepressant that works on both serotonin and norepinephrine and also helps those with chronic pain syndrome,” said Maliuanag, who was not involved in the study.

He added: “Agomelatine unfortunately is not FDA approved in [the] US but I have been aware of early in its trials as a novel antidepressant. [It] works on both serotonin and melatonin, ideal for those with circadian rhythm issues with depression. However, its dose-related effect on liver enzymes, although rarely reported, has been the main obstacle.”

Read more:Whole fruit vs. fruit Juice: Which is better for your heart?

In a press release, Eric Ruhé, MD, PhD, Professor of Difficult to Treat Depression at Radboud University Medical Center, explained: “Of these SSRIs [recommended by many international guidelines], escitalopram now appears to be the most effective, also for long-term use. This study may have implications for future treatment guidelines.”

The researchers compared 20 antidepressants against fluoxetine, which the press release describes as the “best-known antidepressant.”

Escitalopram, agomelatine, and duloxetine all performed better than fluoxetine, suggesting that, even though they are prescribed less commonly than fluoxetine, they may be a more suitable option for long-term use for some people.

“Fluoxetine was chosen as a reference mainly because it is the first in its class and has been around the longest,” said Maliuanag. “If patients are doing well on this medication, they should continue taking it.”

Read more:If FIFA expands the World Cup again, how would a 64-team tournament work?

He added that, if an individual is “a partial or a nonresponder, they should consult their doctor prior to any decision as often an antidepressant is also selected based [on] the individual’s medical profile, medication history, and family history.”

While they performed higher than fluoxetine, escitalopram, agomelatine, and duloxetine may not be suitable for everybody.

For example, Ruhé explained that “agomelatine works well, but one of its side effects is the risk of liver failure.” It is therefore not likely to be a suitable option for people with liver problems or a high risk of liver failure.

MNT asked Maliuanag how likely or even practical it would be for clinicians to regularly recommend escitalopram, agomelatine, or duloxetine to patients with depression, and whether there were any obstacles or other contraindications that need to be considered.

Read more:Could longer exposure to estrogen benefit brain health?

“[T]here are advantages [to] each of these medications but there are certain physical conditions we watch out for. Duloxetine is best avoided with severely impaired kidney function. Escitalopram [is] used with caution with those with [a history of], or [who] may be taking other medications that may cause, QT prolongation, a condition that affects electrical activity of the heart,” Maliuanag told us.

“Agomelatine has been available in Europe and other parts of the world since 2009 but still unavailable in [the] U.S. due to rare cases of liver injury at higher doses. Also, when prescribing an antidepressant, there is always the risk of inducing or unmasking manic symptoms, changing the diagnosis to bipolar disorder,” he added.

“Although this study shows that there are some that may seem more effective than others, antidepressants as a whole are effective but may differ in response for the individual patient. The antidepressant choice should be discussed with their clinician with the intention of looking [at] which may be the right fit based on their presenting symptoms, such as loss of appetite and having trouble sleeping, medical co-morbidities, prior or current substance use or taking other prescription medications, and personal goals.”

– Perry Anthony Maliuanag, MD, FAPA

Read also
Health

Beyond BMI: New obesity definition may better identify health risks

Health

Cardiometabolic disease: How sleep could support brain health

Tags: #AMP #Europe #Family #Has #Participants #review #Will

Journalist

From the same category
  • Beyond BMI: New obesity definition may better identify health risks
  • Cardiometabolic disease: How sleep could support brain health
  • Knee osteoarthritis: 2 trials link new weight-loss drug to pain relief
  • Could longer exposure to estrogen benefit brain health?
  • Experts issue new recommendations for treating shift work disorder
From the same tags
  • Pochettino’s USMNT tenure had ups, downs and an ever-present mercenary feel
  • Beyond BMI: New obesity definition may better identify health risks
  • Corporate Democrats are weaponizing identity politics to smear progressives | Arwa Mahdawi | The Guardian
  • Tearful Pochettino on USMNT exit: Toughest decision of my career
  • What the choice between Chuck Schumer and Chris Van Hollen for Senate leader is all about | Bernie Sanders | The Guardian
Më të lexuarat — 48h
  1. 01
    Opinion What the choice between Chuck Schumer and Chris Van Hollen for Senate leader is all about | Bernie Sanders | The Guardian 2 lexime · 1 day ago
  2. 02
    Health Depression: Escitalopram may be best option for long-term use 2 lexime · 1 day ago
  3. 03
    Football Tearful Pochettino on USMNT exit: Toughest decision of my career 1 lexime · 1 day ago
  4. 04
    Health Beyond BMI: New obesity definition may better identify health risks 1 lexime · 3 hours ago
  5. 05
    Football Pochettino’s USMNT tenure had ups, downs and an ever-present mercenary feel 1 lexime · 3 hours ago
Similar articles
Health

Beyond BMI: New obesity definition may better identify health risks

Evidence suggests that roughly one in seven people are living with obesity, which can increase the risk of…

• 3 hours ago • 9 min read
Health

Cardiometabolic disease: How sleep could support brain health

Getting enough quality sleep could help improve cognitive function in people with type 2 diabetes, heart disease, or…

• 2 days ago • 5 min read
Health

Knee osteoarthritis: 2 trials link new weight-loss drug to pain relief

The knee is the joint most commonly affected by osteoarthritis, a condition in which the cartilage in joints…

• 3 days ago • 6 min read
VA-NEWS VA-NEWS

Modern portal of reliable, independent and multilingual news. Accurate information, every day.

  • Health
  • Lifestyle
  • News
    • World
  • Opinion
  • Sport
    • Football
  • uncategorized
  • © 2026 VA News. Made with ♥ in Albania
    ⌂ Home ◷ Latest

    Powered by CookieAdmin
    Necessary cookies enable essential site features like secure log-ins and consent preference adjustments. They do not store personal data.
    None
    Functional cookies support features like content sharing on social media, collecting feedback, and enabling third-party tools.
    None
    Analytical cookies track visitor interactions, providing insights on metrics like visitor count, bounce rate, and traffic sources.
    None
    Advertisement cookies deliver personalized ads based on your previous visits and analyze the effectiveness of ad campaigns.
    None
    Unclassified cookies are cookies that we are in the process of classifying, together with the providers of individual cookies.
    None
    Powered by CookieAdmin